948303-89-7

Upstream product

• 478832-23-4 cis-4-nitrobenzoic acid 4-(1,3-dioxo-1,3-dihydroisoindol-2-yl)cyclohexyl ester 
• 50910-54-8 trans-4-aminocyclohexanol hydrochloride 
• 478832-25-6 2-(cis-4-hydroxycyclohexyl)isoindoline-1,3-dione 
• 62-23-7 4-nitro-benzoic acid 
• 99337-98-1 2-((1R,4R)-4-hydroxycyclohexyl) isoindoline-1,3-dione 

Downstream Products

• 948303-93-3 cis-4-nitrobenzoic acid 4-(3-adamantan-1-ylureido)cyclohexyl ester 
• 885009-99-4 cis-1-(4-hydroxy-cyclohexyl)-3-tricyclo[3.3.1.13,7]decan-1-yl-urea 
• 1394012-00-0 cis-4-nitrobenzoic acid 4-[3-(4-chloro-3-trifluoromethylphenyl)ureido]cyclohexyl ester 
• 1394012-01-1 cis-1-(4-chloro-3-trifluoromethylphenyl)-3-(4-hydroxycyclohexyl)urea 
• 1394011-94-9 cis-4-{4-[3-(4-chloro-3-trifluoromethylphenyl)ureido]cyclohexyloxy}pyridine-2-carboxylic acid tert-butyl ester 
• 1394012-02-2 cis-4-{4-[3-(4-chloro-3-trifluoromethylphenyl)ureido]cyclohexyloxy}pyridine-2-carboxylic acid methylamide 
• 1394012-04-4 C₂HF₃O₂*C₂₀H₁₉ClF₃N₃O₄ 

Relevant academic research and scientific papers

Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors

To reduce the pro-angiogenic effects of sEH inhibition, a structure-activity relationship (SAR) study was performed by incorporating structural features of the anti-angiogenic multi-kinase inhibitor sorafenib into soluble epoxide hydrolase (sEH) inhibitors. The structural modifications of this series of molecules enabled the altering of selectivity towards the pro-angiogenic kinases C-RAF and vascular endothelial growth factor receptor-2 (VEGFR-2), while retaining their sEH inhibition. As a result, sEH inhibitors with greater potency against C-RAF and VEGFR-2 were obtained. Compound 4 (t-CUPM) possesses inhibition potency higher than sorafenib towards sEH but similar against C-RAF and VEGFR-2. Compound 7 (t-CUCB) selectively inhibits sEH, while inhibiting HUVEC cell proliferation, a potential anti-angiogenic property, without liver cancer cell cytotoxicity. The data presented suggest a potential rational approach to control the angiogenic responses stemming from sEH inhibition.

SORAFENIB DERIVATIVES AS sEH INHIBITORS

The present invention provides compounds for the inhibition of soluble epoxide hydrolase and associated disease conditions.

Orally bioavailable potent soluble epoxide hydrolase inhibitors

A series of N,N′-disubstituted ureas having a conformationally restricted cis- or trans-1,4-cyclohexane α to the urea were prepared and tested as soluble epoxide hydrolase (sEH) inhibitors. This series of compounds showed low nanomolar to picomolar activi